* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Elicited Behavior and Classical Conditioning
Specialty drugs in the United States wikipedia , lookup
Discovery and development of non-nucleoside reverse-transcriptase inhibitors wikipedia , lookup
Polysubstance dependence wikipedia , lookup
Pharmaceutical marketing wikipedia , lookup
Compounding wikipedia , lookup
Orphan drug wikipedia , lookup
Drug design wikipedia , lookup
Neuropsychopharmacology wikipedia , lookup
Psychopharmacology wikipedia , lookup
Neuropharmacology wikipedia , lookup
Pharmacokinetics wikipedia , lookup
Pharmacogenomics wikipedia , lookup
Pharmacognosy wikipedia , lookup
Drug interaction wikipedia , lookup
Drug discovery wikipedia , lookup
Pharmacology for the Health Sciences Lecture 3 Dr. Steven I. Dworkin How are Drugs Named? • Chemical Name – Specifies chemical structure • Pre patent or release name – Typically drug company letters and numbers • Generic Name – Nonproprietary name (each drug has only one generic name) • Brand or Trade Name – Market name for a particular company • Common or Street Name – Users name Dr. Steven I. Dworkin What’s in a Name Chemical Name Generic Name Trade Name N-(4-hydroxyphenyl) acetamide Acetaminophen Tylenol Diazepam Valium 4-[4-(p-chlorophenyl)-4-hydroxypiperidino]-4'fluorobutyrophenone Haloperidol Haldol 5-thia-1-azabicyclo [4.2.0]-oct-2-ene-2 carboxylic acid, 7[(aminophenylacetyl)amino]-3-methyl-8-oxo-, monohydrate Cephalexin Keflex, Keforal, Keftabs DL-threo-2-(methylamino)-1-phenylpropan-1ol Pseudoephedrine Sudafed Cimetidine Tagamet 7-chloro-1,3-dihydro-1-methyl-5-phenyl-2H1,4-benzodiazepin-2-one N''-cyano-N-methyl-N'-[2-[[(5-methyl-1Himidazol-4-yl) methyl]thio]ethyl]guanidine Dr. Steven I. Dworkin Rose Chemical Name isobutylphenyl propionic acid In-house name Generic Name ibuprofen Brand Names Advil, Children's Advil/Motrin, Medipren, Motrin, Nuprin, Pediacare Fever etc Street Non-asprin headache reliever Dr. Steven I. Dworkin ibuprofen (ī'byūprō'fən) , nonsteroidal anti-inflammatory drug (NSAID) that reduces pain, fever, and inflammation. Along with naproxen and ketoprofen, ibuprofen belongs to the propionic acid class of NSAIDs. It was first made available in 1967. Like other NSAIDs, it acts by inhibiting the body's production of prostaglandins. Available over the counter in a variety of preparations (e.g., Advil, Motrin, Nuprin), it is commonly used to treat rheumatoid arthritis, gout, and painful menstruation. Side effects include rash, alteration of platelet function and bleeding, and intestinal upset, which can lead to gastritis. Like other NSAIDS, it appears to have no potential for abuse or physical dependence. It should not be used by those who are allergic to aspirin. Drug Resources Dr. Steven I. Dworkin Classification of Drugs • Grouping by chemical structure. Specific Examples Core Structure Generic Name Trade Name Tetracyclines Doxycycline Vibramycine Corticosteroids Prednisone Meticorten Benzodiazepines Diazepam Valium Dr. Steven I. Dworkin Classification of Drugs • Mechanism of action – Serotonin uptake inhibitors • antidepressants – beta blockers • Anti-hypertensives – H2 blockers • Anti-histamines Dr. Steven I. Dworkin Drug Classification Therapeutic Category • Therapeutic Categories and Subcategories Examples of Subcategories Analygesics NSAIDs Opioids Antibiotics Tetracyclines Penicillins Cephalosporins Antihypertensive b2 –Blockers Diuretics ACE Inhibitors Anti-inflammatory drugs NSAIDs Corticosteroids Asthma Drugs b2 –Blockers Corticosteroids Leukotriene modifiers Dr. Steven I. Dworkin Drug Classification Classification Characteristics OTC drugs Drugs that do not require a prescription. May contain a lower dose of a prescribed compound, Prescription drugs Greater potential for adverse effects. Untoward drug interactions may occur. Use is monitored by a physician. Controlled Substances Schedules drugs evaluated for abuse liability. More restrictive requirements regarding distribution, storage, and record keeping Dr. Steven I. Dworkin The Feds Year Act Purpose Comment 1906 Federal Pure food act Prohibit adulteration and misbranding of medications USP standards established for ingredients. Drug did not have to be safe or effective 1938 Drug and Cosmetic Act Required safety of new drug approval by FDA Start of NDA process 1952 DurhamHumphrey Amendment Differentiated prescription and nonprescription Drugs unsafe without medical supervision required prescription, refill restriction 1962 Kefauver-Harris Amendment Required effectiveness of prescription and nonprescription approval by FDA Drugs developed between 19381962 included 1970 Comprehensive Drug Abuse Act Established Categories for drugs with abuse potential. DEA to enforce the act Dr. Steven I. Dworkin Dr. Steven I. Dworkin Dr. Steven I. Dworkin Dr. Steven I. Dworkin Pre Clinical Trials • In vitro studies • In vivo studies – Use of standard animal models • Efficacy • Potency • Safety • LD determination • ED determinations – Therapeutic Ratio • Abuse Potential or Liability – Drug self-administration Dr. Steven I. Dworkin Clinical Trials • Introduction – Before a pharmaceutical company can initiate testing in humans, it must conduct extensive preclinical or laboratory research. • Preclinical research typically involves years of experiments in animal and human cells. The compounds are also extensively tested in animals. • 100-300k compounds screens 100-300 compounds 1 or 2 lead compounds • Pharmaceutical company provides selected data to the Food and Drug Administration (FDA) with a requesting approval to begin testing the drug in humans. • This is called an Investigational New Drug application (IND). • Typically this is when the clock starts clicking and the PC has the next 11 years of exclusive patent rights. Dr. Steven I. Dworkin Phase Purpose Subjects Duration Outcome Phase I how drug absorbed, metabolized, and excreted and side effects over range of doses healthy volunteers (20 to 100), who are usually paid for participating in the study. several months 70 percent of experimental drugs pass this initial phase of testing Phase II determine relative safety of the new drug, and its effectiveness. . several hundred patients randomized trials, drug vs control often blinded. several months to two years 33 percent of experimental drugs successfully complete both phase I and phase II studies Phase III provide drug company and the FDA with a more thorough understanding of the drug's effectiveness, benefits, and the range of possible adverse reactions. several hundred to several thousand patients., most phase III studies are randomized and blinded trials. several years Seventy to 90 percent of drugs that enter phase III studies successfully complete this phase of testing FDA approval for market ing the drug. Phase IV objectives: (1) studies often compare a drug with other drugs already in the market; (2) studies are often designed to monitor a drug's long-term effectiveness and impact on a patient's quality of life; and (3) many studies are designed to determine the cost-effectiveness of a drug therapy relative to other traditional and new therapies. Dr. Steven I. Dworkin Issues • • • • • • • • The New Drug War (non-US markets) Involvement of Pharmaceutical Companies Involvement of Interest Groups Role of advisory panel Role of FDA officials Publication and disclosure of negative findings When things go wrong? – Cox-2 inhibitors Media – Steroids – Alternative Medications Dr. Steven I. Dworkin Questions • Why are drugs categorized? • What are the major differences between name brand and generics drugs? • Approximately how many drugs are tested for every drug that is approved ? • What federal agency is responsible for determining the safety and efficacy of new pharmaceuticals? • What federal agency is responsible for enforcing the regulations for scheduled compounds • What are the basic differences between OTC and prescription drugs? • Under what conditions can a schedule I drug be prescribed for a patient. • Name 2 Schedule II and 3 Schedule III compounds, what is one major difference between these compounds (difference of Schedule II compared to Schedule III) ? • Who is responsible for the appropriate use of a compound? Dr. Steven I. Dworkin